- Younger Adults with High LDL-C Levels and Statins
Younger Adults with High LDL-C Levels and Statins
Despite recommendations, less than 45 percent of adults younger than 40 years with an elevated low-density lipoprotein cholesterol (LDL-C) level of 190 mg/dL or greater receive a prescription for a statin, according to a study published online by JAMA Cardiology.
Cardiovascular disease affects 1 in 3 patients and remains the leading cause of death in the United States. Severe elevation of LDL-C levels is a modifiable risk factor for developing premature cardiovascular disease. Treatment with statins is recommended for all adults 21 years or older with an LDL-C of 190 mg/dL or greater, with treatment appearing to reduce the risk of death and result in cost savings for health systems.
David A. Zidar, M.D., Ph.D., of University Hospitals Cleveland Medical Center, Cleveland, and colleagues examined rates of statin prescription in patients screened for dyslipidemia (a disorder of lipoprotein metabolism, including lipoprotein overproduction or deficiency) to identify treatment gaps. For the analysis, the researchers used a national clinical registry that encompasses data from inpatient and outpatient encounters from 360 medical centers in all 50 states, and included all patients between age 20 and 75 years who had both LDL-C and pharmacy records reported between July 1, 2013, and July 31, 2016.
Of the 2,884,260 patients with a qualifying lipid analysis, 3.8 percent had an LDL-C of l90 mg/dL or greater. The statin prescription rate for patients with severe dyslipidemia but without diabetes or established atherosclerotic cardiovascular disease (ASCVD) was 66 percent. Even with more severe elevations in LDL-C levels (LDL-C>250 mg/dL and LDL-C> 300 mg/dL), 25 percent of patients were not prescribed a statin.
Notably, statin prescription rates for patients with severe dyslipidemia varied sharply by age, with significantly lower rates in younger patients. Statins were prescribed in only 32 percent, 47 percent, and 61 percent of patients in their 30s, 40s, and 50s, respectively. “This finding has particular relevance given the early onset of ASCVD and cardiovascular death observed infamilial hypercholesterolemia studies from the pre-statin era,” the authors write. “Specific interventions that optimize the follow-up of younger patients after lipid screening may be needed to realize the potential for improved survival and cost reduction associated with the treatment of severe dyslipidemia.”
(JAMA Cardiology. Published online January 4, 2017; doi:10.1001/jamacardio.2016.4792.
DISCLAIMER: Bankix Systems Ltd is the registered name of a Canadian firm since 2003, and bankixsystems.com is its OFFICIAL website. Besides these entities, we have no relationship with anyone, business, website, or any other entity anywhere in the world, claiming to be Bankix Systems, or using a similar name, and creating the impression that it has some connection with our company. We do not endorse and are therefore, not responsible for any act or lack thereof by any such entity. Bankix Systems Ltd is also not responsible for the content of the description of products and services linked to our site nor does it necessarily endorse them. The information here provided is not for diagnosing/treating your health concerns. Kindly contact your doctor or health care professional for all your healthcare requirements.
Contents © 2003-2019, BankixSystems.com. All rights reserved. Unauthorized reproduction strictly prohibited. Information based on best available resources. Opinions are current and subject to change.